Antibody production: policlonal derived biotherapeutis

download Antibody production: policlonal derived biotherapeutis

of 15

Transcript of Antibody production: policlonal derived biotherapeutis

  • 8/12/2019 Antibody production: policlonal derived biotherapeutis

    1/15

  • 8/12/2019 Antibody production: policlonal derived biotherapeutis

    2/15

    Abstract

    Antibody based therapies using monoclonal orpolyclonal antibodies are emerging as an important therapeutic

    approach for the treatment of a number of diseases. With

    increasing emphasis on new technologies associated with

    monoclonal antibody expression and purification, the clinical

    need of polyclonal therapeutics for treatment of a variety of

    specific illnesses and infections is often overlooked. Despitebeing largely abandoned in the early twentieth century due to the

    development of antibiotics, polyclonal antibody therapeutics are

    today widely used in medicine for viral and toxin neutralization

    and for replacement therapy in patients with immunoglobulin

    deficiencies. Over the past 20 years, intravenous

    immunoglobulins have shown beneficialimmunomodulatory andanti-inflammatory effects in many illnesses. Hyperimmune

    antibody preparations have been used over the past century for

    the treatment of a variety of infectious agents and medical

    emergencies, including digoxin toxicity, snake envenomation and

    spider bites. Here, we examine the contemporary techniques and

    applications, and assess the future therapeutic potential, forpolyclonal-derived antibody therapeutics.

  • 8/12/2019 Antibody production: policlonal derived biotherapeutis

    3/15

    Antibodies play an important role in

    the defense against pathogens. They

    specifically recognize and bind toforeign antigens, resulting in the

    activation of a number of immune

    effector functions capable ofselectively eliminating foreign

    micro-organisms, viruses and

    molecules.

  • 8/12/2019 Antibody production: policlonal derived biotherapeutis

    4/15

  • 8/12/2019 Antibody production: policlonal derived biotherapeutis

    5/15

  • 8/12/2019 Antibody production: policlonal derived biotherapeutis

    6/15

  • 8/12/2019 Antibody production: policlonal derived biotherapeutis

    7/15

  • 8/12/2019 Antibody production: policlonal derived biotherapeutis

    8/15

  • 8/12/2019 Antibody production: policlonal derived biotherapeutis

    9/15

  • 8/12/2019 Antibody production: policlonal derived biotherapeutis

    10/15

  • 8/12/2019 Antibody production: policlonal derived biotherapeutis

    11/15

    TRANSGENIC POLYCLONAL THERAPEUTICS

    L A R G E - S C A L E P R O D U C T I O N O F H U M A N

    P O LY C L O N A L A N T I B O D I E S U S I N G H U M A N

    A R T I F I C I A L C H R O M O S O M E ( H A C ) W I T H

    T R A N S G E N I C P R O C E S S .

    H A C C O N T A I N C H R O M O S O M E N U M B E R 2 2

    W I T H A N T I B O D Y E X P R E S S I O N .

    H E M A T E C H L C C ( C O N N E C T I C U T, U S A ) C A L V E S ;

    T H E R A U P E T I C H U M A N P O LY C L O N A L S I N C .

    ( C A L I F O R N I A , U S A )

    R A B B I T ; O R I G E N T H E R A P E U T I C I N C ( U S A )A V I A N

    E M B R Y O N I C C E L L .

  • 8/12/2019 Antibody production: policlonal derived biotherapeutis

    12/15

  • 8/12/2019 Antibody production: policlonal derived biotherapeutis

    13/15

    POLYCLONAL ANTIBODIES FOR

    BIODEFENSE APPLICATIONS

    C O M B AT B I O L O G I C A L W A R FA R E A G E N T S B Y

    M I M I C K I N G T H E P A S S I V E I M M U N I Z A T I O N .

    W I L L B E A D VA N TA G E O U S , B U T T H E R E R E

    S O M E F A C T O R S N E E D T O B E C O N S I D E R E D :

    Immune response to a pathogen doesnt always

    correlate to protective immunity;

    Role of memory B cells in long term immunity often

    depends on the incubation period of pathogen. O F F E R I N G C L I N I C A L P R O T E C T I O N

    I M M E D I AT E L Y A F T E R E X P O S U R E T O

    PAT H O G E N I C B A C T E R I A S O R V I R U S E S .

  • 8/12/2019 Antibody production: policlonal derived biotherapeutis

    14/15

    THE FUTURE OF POLYCLONAL ANTIBODY

    THERAPEUTICS

    M O N O C L O N A L A N D P O L Y C L O N A L

    A N T I B O D I E S .

    N E O VA C S S A ( F R A N C E )A N T I - C Y T O K I N E

    T H E R A P E U T I C S , T R E AT M E N T O F H I V.

    A D VA N TA G E S O F P O LY C L O N A L A N T I B O D Y.

  • 8/12/2019 Antibody production: policlonal derived biotherapeutis

    15/15